M
Mythic Therapeutics
Making better antibody-drug conjugates (adcs) that deliver chemotherapy directly to tumors while avoiding payload release in normal cells
About Mythic Therapeutics
Mythic Therapeutics is a biotechnology startup that operates in the healthcare sector, specifically in the field of cancer treatment. The company's primary focus is on the development and commercialization of antibody-drug conjugates (ADCs), a type of targeted chemotherapy. ADCs are designed to deliver chemotherapy directly to cancer cells, thereby reducing the impact on healthy tissues. However, the current challenge with ADCs is that more than 95% of the dose often ends up in healthy tissues, which decreases the drug's effectiveness and increases toxicity.
Read full description
Mythic's innovative solution to this problem is their proprietary technology, FateControl™. This technology increases the uptake of ADCs in cancer cells while preventing payload release in normal cells. The result is a significant increase in the effectiveness of the treatment for a wide range of cancer types, without causing unacceptable side effects or toxicity. This could potentially lead to better treatment outcomes for a broader patient population.
Mythic Therapeutics operates on a business model that involves the development of this technology and its application in creating more effective cancer treatments. The company generates revenue through the commercialization of its technology and the development of new treatments.
The team at Mythic is composed of experienced entrepreneurs and innovators, who are dedicated to improving patient outcomes through their work. They are committed to changing the state of the art in cancer treatment, bringing us closer to realizing the full potential of ADCs for patients across the world.
At a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Waltham, United States
- Employees
- 11
- Open positions
- None listed
- Dealroom signal
- 60.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Mythic Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Dec 2021 | $103M | $412M | Venrock · Refactor Capital · Lifeforce Capital · OMX Ventures | ↗ |
| SERIES AOther financing | Aug 2020 | $24M | $94M | Venrock · BoxGroup | — |
Growth signals
Latest recorded traffic for Mythic Therapeutics is 2.6K monthly website visits, up 30% over the last three months. Mythic Therapeutics's team declined 65.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A9 investors entered at this stage
Venrock
BoxGroup
Viking Global Investors
Refactor Capital
Lifeforce Capital
OMX Ventures
Foresite Capital
Perceptive Advisors
Highside Capital Management
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Mythic Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Mythic Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.